The similar effects of sparsentan and losartan on glomerulosclerosis and tissue fibrosis (Figure 6C), despite the clear benefit of sparsentan versus losartan treatment on other parameters such as podocyte number (Figure 6, A and B), suggest that 6 weeks of treatment may not be sufficiently long or the disease stage was too advanced (mice were 1.5 years old) to translate into improved histological readouts in a slowly developing FSGS model such as the applied TRPC6-Tg mouse model. The gene discussed is TRPC6; the disease is focal segmental glomerulosclerosis.